AIMS: Transcatheter aortic valve implantation (TAVI) is an increasingly common procedure in elderly and multimorbid patients with aortic stenosis. We aimed at developing a pre-procedural risk evaluation scheme beyond current surgical risk scores. METHODS: We developed a risk algorithm for 1-year mortality in two cohorts consisting of 845 patients undergoing routine TAVI procedures by commercially available devices, mean age 80.9 ± 6.5, 51 % women. Clinical variables were determined at baseline. Multivariable Cox regression related clinical data to mortality (n = 207 deaths). RESULTS: To account for variability related to age and sex and by enrolment site we forced age, sex, and cohort into the score model. Body mass index, estimated glomerular filtration rate, hemoglobin, pulmonary hypertension, mean transvalvular gradient and left ventricular ejection fraction at baseline were most strongly associated with mortality and entered the risk prediction algorithm [C-statistic 0.66, 95 % confidence interval (CI) 0.61-0.70, calibration χ (2)-statistic = 6.51; P = 0.69]. Net reclassification improvement compared to existing surgical risk predication schemes was positive. The score showed reasonable model fit and calibration in external validation in 333 patients, N = 55 deaths (C-statistic 0.60, 95 % CI 0.52-0.68; calibration χ (2)-statistic = 16.2; P = 0.06). Additional measurement of B-type natriuretic peptide and troponin I did not improve the C-statistic. Frailty increased the C-statistic to 0.71, 95 % CI 0.65-0.76. CONCLUSIONS: We present a new risk evaluation tool derived and validated in routine TAVI cohorts that predicts 1-year mortality. Biomarkers only marginally improved risk prediction. Frailty increased the discriminatory ability of the score and needs to be considered. Risk algorithms specific for TAVI may help to guide decision-making when patients are evaluated for TAVI.
AIMS: Transcatheter aortic valve implantation (TAVI) is an increasingly common procedure in elderly and multimorbid patients with aortic stenosis. We aimed at developing a pre-procedural risk evaluation scheme beyond current surgical risk scores. METHODS: We developed a risk algorithm for 1-year mortality in two cohorts consisting of 845 patients undergoing routine TAVI procedures by commercially available devices, mean age 80.9 ± 6.5, 51 % women. Clinical variables were determined at baseline. Multivariable Cox regression related clinical data to mortality (n = 207 deaths). RESULTS: To account for variability related to age and sex and by enrolment site we forced age, sex, and cohort into the score model. Body mass index, estimated glomerular filtration rate, hemoglobin, pulmonary hypertension, mean transvalvular gradient and left ventricular ejection fraction at baseline were most strongly associated with mortality and entered the risk prediction algorithm [C-statistic 0.66, 95 % confidence interval (CI) 0.61-0.70, calibration χ (2)-statistic = 6.51; P = 0.69]. Net reclassification improvement compared to existing surgical risk predication schemes was positive. The score showed reasonable model fit and calibration in external validation in 333 patients, N = 55 deaths (C-statistic 0.60, 95 % CI 0.52-0.68; calibration χ (2)-statistic = 16.2; P = 0.06). Additional measurement of B-type natriuretic peptide and troponin I did not improve the C-statistic. Frailty increased the C-statistic to 0.71, 95 % CI 0.65-0.76. CONCLUSIONS: We present a new risk evaluation tool derived and validated in routine TAVI cohorts that predicts 1-year mortality. Biomarkers only marginally improved risk prediction. Frailty increased the discriminatory ability of the score and needs to be considered. Risk algorithms specific for TAVI may help to guide decision-making when patients are evaluated for TAVI.
Authors: Philippe Généreux; Stuart J Head; Nicolas M Van Mieghem; Susheel Kodali; Ajay J Kirtane; Ke Xu; Craig Smith; Patrick W Serruys; A Pieter Kappetein; Martin B Leon Journal: J Am Coll Cardiol Date: 2012-04-11 Impact factor: 24.094
Authors: Alexander Sedaghat; Jan-Malte Sinning; Mariuca Vasa-Nicotera; Alexander Ghanem; Christoph Hammerstingl; Eberhard Grube; Georg Nickenig; Nikos Werner Journal: Clin Res Cardiol Date: 2013-07-23 Impact factor: 5.460
Authors: Diego López-Otero; Ramiro Trillo-Nouche; Francisco Gude; Belen Cid-Álvarez; Raimundo Ocaranza-Sanchez; Melisa Santas Alvarez; Pamela V Lear; José R Gonzalez-Juanatey Journal: Int J Cardiol Date: 2012-12-30 Impact factor: 4.164
Authors: Josep Rodés-Cabau; Marcos Gutiérrez; Rodrigo Bagur; Robert De Larochellière; Daniel Doyle; Mélanie Côté; Jacques Villeneuve; Olivier F Bertrand; Eric Larose; Juan Manazzoni; Philippe Pibarot; Eric Dumont Journal: J Am Coll Cardiol Date: 2011-05-17 Impact factor: 24.094
Authors: Thomas Pilgrim; Bindu Kalesan; Peter Wenaweser; Christoph Huber; Stefan Stortecky; Lutz Buellesfeld; Ahmed A Khattab; Balthasar Eberle; Steffen Gloekler; Thomas Gsponer; Bernhard Meier; Peter Jüni; Thierry Carrel; Stephan Windecker Journal: Circ Cardiovasc Interv Date: 2012-11-20 Impact factor: 6.546
Authors: Martyn Thomas; Gerhard Schymik; Thomas Walther; Dominique Himbert; Thierry Lefèvre; Hendrik Treede; Holger Eggebrecht; Paolo Rubino; Iassen Michev; Rüdiger Lange; William N Anderson; Olaf Wendler Journal: Circulation Date: 2010-06-21 Impact factor: 29.690
Authors: Felipe C Fuchs; Christoph Hammerstingl; Jan-Malte Sinning; Fritz Mellert; Nikos Werner; Eberhard Grube; Georg Nickenig Journal: Clin Res Cardiol Date: 2015-11-09 Impact factor: 5.460
Authors: Marcel Weber; Eva Brüggemann; Robert Schueler; Diana Momcilovic; Jan-Malte Sinning; Alexander Ghanem; Nikos Werner; Eberhard Grube; Wolfgang Schiller; Fritz Mellert; Armin Welz; Georg Nickenig; Christoph Hammerstingl Journal: Clin Res Cardiol Date: 2015-05-13 Impact factor: 5.460